Pharmaceuticals, Biotechnology and Life Sciences
KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of…
The results of this study provide evidence of the potential benefit of MK-6482 and support further investigation into how this HIF-2α inhibitor could play a meaningful role for these patients
Data Show KEYTRUDA Monotherapy Significantly Reduced the Risk of Disease Progression or Death by 35% Compared with BV
First Combination Data in Stage III NSCLC from KEYNOTE-799 Showed KEYTRUDA Plus Concurrent Chemoradiation Achieved Objective Response Rate of 67.0%…
Te U.S. Food and Drug Administration (FDA) approved the myChoice CDx test for use as a companion diagnostic by healthcare professionals to identify certaikn advanced ovarian cancer patients.
U.S. Food and Drug Administration (FDA) Accepted for Review a Supplemental New Drug Application (sNDA) for RECARBRIO in Hospital-Acquired or…
FDA has approves Merck’s Keytruda, pembrolizumab, for use at an additional recommended dose of 400 mg every six weeks for all approved adult indications.
Data showed the efficacy and safety of Keytruda 400 mg every six weeks (Q6W) comparable to approved 200 mg every three weeks (Q3W) regimen.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the Institute for Systems Biology (ISB), today announced a new research collaboration to investigate and define the molecular mechanisms of SARS-CoV-2 infection and COVID-19 and identify targets for medicines and vaccines.
AstraZeneca and Merck revealed further positive results from the Phase 3 PROfound trial evaluating LYNPARZA in men with metastatic castration-resistant prostate cancer (mCRPC).